Page last updated: 2024-08-03 05:42:03
exendin (9-39)
Description
exendin (9-39): a peptide from the venom of the lizard Heloderma suspectum; inhibits glucagon-like peptide-1 (GLP-1) induced cAMP production; its structure is related to exendin-4 [MeSH]
Cross-References
Synonyms (15)
| Synonym |
|---|
| avexitide |
| exendin (9-39) |
| 133514-43-9 |
| exendin-3 (9-39) amide |
| AKOS024456934 |
| J-006390 |
| exendin-3 (9-39) |
| exendin-3 9-39)amide |
| EX-A7432 |
| CHEMBL4070972 |
| asp-leu-ser-lys-gln-met-glu-glu-glu-ala-val-arg-leu-phe-ile-glu-tr|p|-leu-lys-asn-gly-gly-pro-ser-ser-gly-ala-pro-pro-pro-ser-nh2 |
| cid 16198321 |
| DTXSID00158156 |
| asp-leu-ser-lys-gln-met-glu-glu-glu-ala-val-arg-leu-phe-ile-glu-trp-leu-lys-asn-gly-gly-pro-ser-ser- |
| AS-83777 |
Bioassays (1)
Research
Studies (245)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 37 (15.10) | 18.2507 |
| 2000's | 62 (25.31) | 29.6817 |
| 2010's | 129 (52.65) | 24.3611 |
| 2020's | 17 (6.94) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 23 (9.31%) | 5.53% |
| Reviews | 6 (2.43%) | 6.00% |
| Case Studies | 1 (0.40%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 217 (87.85%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| gamma-aminobutyric acid | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid | human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbamates | | amino-acid anion | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| choline | | cholines | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorine | | halide anion;
monoatomic chlorine | cofactor;
Escherichia coli metabolite;
human metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydrochloric acid | | chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride | mouse metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| formaldehyde | | aldehyde;
one-carbon compound | allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| histamine | | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| palmitic acid | | long-chain fatty acid;
straight-chain saturated fatty acid | algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| uracil | | pyrimidine nucleobase;
pyrimidone | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-anilino-8-naphthalenesulfonate | | aminonaphthalene;
naphthalenesulfonic acid | fluorescent probe | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2011 | 2015 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| am 251 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles | antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diazoxide | | benzothiadiazine;
organochlorine compound;
sulfone | antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent | 1999 | 2023 | 15.0 | low | 0 | 0 | 1 | 1 | 0 | 1 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanethidine | | azocanes;
guanidines | adrenergic antagonist;
antihypertensive agent;
sympatholytic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-(5-isoquinolinesulfonyl)-2-methylpiperazine | | isoquinolines;
N-sulfonylpiperazine | EC 2.7.11.13 (protein kinase C) inhibitor | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexamethonium | | quaternary ammonium salt | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2007 | 2009 | 16.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| 1-methyl-3-isobutylxanthine | | 3-isobutyl-1-methylxanthine | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| kynurenic acid | | monohydroxyquinoline;
quinolinemonocarboxylic acid | G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ondansetron | | carbazoles | | 2014 | 2019 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pd 98059 | | aromatic amine;
monomethoxyflavone | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| proglumide | | benzamides;
dicarboxylic acid monoamide;
glutamine derivative;
racemate | anti-ulcer drug;
cholecystokinin antagonist;
cholinergic antagonist;
delta-opioid receptor agonist;
drug metabolite;
gastrointestinal drug;
opioid analgesic;
xenobiotic metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ro 31-8220 | | imidothiocarbamic ester;
indoles;
maleimides | EC 2.7.11.13 (protein kinase C) inhibitor | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rolipram | | pyrrolidin-2-ones | antidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| saccharin | | 1,2-benzisothiazole;
N-sulfonylcarboxamide | environmental contaminant;
sweetening agent;
xenobiotic | 1997 | 2013 | 17.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| corticosterone | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 1997 | 2018 | 13.7 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 1998 | 2012 | 19.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| aspartic acid | | aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
mouse metabolite;
neurotransmitter | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| glutamine | | amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| lysine | | aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid | algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2003 | 2004 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aminopyrine | | pyrazolone;
tertiary amino compound | antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| galactose | | D-galactose;
galactopyranose | Escherichia coli metabolite;
mouse metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenylalanine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid | algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 1995 | 2014 | 19.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| quinoxalines | | mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| xanthenes | | xanthene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dimethyl succinate | | fatty acid methyl ester | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinazolines | | azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adamantane | | adamantanes;
polycyclic alkane | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| pyrazines | | diazine;
pyrazines | Daphnia magna metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| malondialdehyde | | dialdehyde | biomarker | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dideoxyadenosine | | adenosines;
purine 2',3'-dideoxyribonucleoside | EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| technetium | | manganese group element atom | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-deoxynojirimycin | | 2-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid | anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite | 2011 | 2019 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 1999 | 2004 | 21.7 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| ng-nitroarginine methyl ester | | alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor | 2007 | 2009 | 16.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| deoxynivalenol | | cyclic ketone;
enone;
primary alcohol;
secondary alpha-hydroxy ketone;
trichothecene;
triol | mycotoxin | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| colforsin | | acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol | adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2',5'-dideoxyadenosine | | deoxyribonucleoside | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triazoles | | 1,2,3-triazole | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tyloxapol | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| loganin | | beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol | anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-succinimidyl-3-(4-hydroxyphenyl)propionate | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluo-3 | | xanthene dye | fluorochrome | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| geniposide | | terpene glycoside | | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| deoxyglucose | | | | 2005 | 2007 | 18.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| glicentin | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| xylose | | D-xylose | | 1996 | 2008 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| atropine | | | | 2007 | 2009 | 16.3 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| wortmannin | | acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound | anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lithium chloride | | inorganic chloride;
lithium salt | antimanic drug;
geroprotector | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glycogen | | | | 1997 | 2005 | 22.8 | low | 0 | 0 | 2 | 2 | 0 | 0 |
| oxytocin | | heterodetic cyclic peptide;
peptide hormone | oxytocic;
vasodilator agent | 1997 | 2014 | 17.5 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| nitroarginine | | guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid | | 1998 | 2010 | 19.7 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| miglitol | | piperidines | | 2011 | 2019 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| geniposidic acid | | terpene glycoside | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| devazepide | | 1,4-benzodiazepinone;
indolecarboxamide | antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug | 2007 | 2015 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thapsigargin | | butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone | calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| h 89 | | N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide | | 2009 | 2020 | 11.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| iridoids | | | | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 1997 | 2002 | 24.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fg 9041 | | quinoxaline derivative | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| linoleic acid | | octadecadienoic acid;
omega-6 fatty acid | algal metabolite;
Daphnia galeata metabolite;
plant metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2005 | 2017 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cp 99994 | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| l 365260 | | benzodiazepine | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nateglinide | | phenylalanine derivative | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enkephalin, ala(2)-mephe(4)-gly(5)- | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tetrodotoxin | | azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid | animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker | 2004 | 2017 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| vildagliptin | | amino acid amide | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| biie 0246 | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mocetinostat | | aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| shu 9119 | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dirlotapide | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| linagliptin | | aminopiperidine;
quinazolines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alogliptin | | nitrile;
piperidines;
primary amino compound;
pyrimidines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sitagliptin phosphate | | | | 2013 | 2016 | 9.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| scopolamine hydrobromide | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pituitrin | | | | 1997 | 2001 | 25.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| calcitonin | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cholecystokinin | | | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glucagon-like peptide 1 (7-36)amide | | | | 1994 | 2011 | 23.7 | medium | 0 | 0 | 18 | 5 | 3 | 0 |
| glucagon | | peptide hormone | | 1994 | 2021 | 20.9 | medium | 7 | 0 | 38 | 26 | 17 | 1 |
| neuropeptide y | | | | 1996 | 2012 | 21.3 | low | 0 | 0 | 2 | 0 | 1 | 0 |
| astressin | | homodetic cyclic peptide;
polypeptide | corticotropin-releasing factor receptor antagonist;
neuroprotective agent | 2000 | 2007 | 20.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| glucagon-like peptide 1 (7-36) | | | | 1997 | 2004 | 22.7 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| liraglutide | | lipopeptide;
polypeptide | glucagon-like peptide-1 receptor agonist;
neuroprotective agent | 2011 | 2020 | 8.3 | low | 0 | 0 | 0 | 0 | 6 | 0 |
| glucagon-like peptide 1 | | | | 1994 | 2023 | 15.6 | high | 14 | 0 | 39 | 47 | 82 | 5 |
| incretins | | | | 2007 | 2021 | 9.7 | low | 3 | 0 | 0 | 1 | 10 | 1 |
| c-peptide | | | | 1998 | 2016 | 14.5 | low | 3 | 0 | 1 | 0 | 3 | 0 |
| endothelin-1 | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| neurotensin | | peptide hormone | human metabolite;
mitogen;
neurotransmitter;
vulnerary | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| jnj-31020028 | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| piperidines | | | | 2014 | 2016 | 9.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| exenatide | | | | 1993 | 2021 | 16.1 | medium | 3 | 0 | 11 | 16 | 26 | 1 |
| vasoactive intestinal peptide | | | | 1995 | 2012 | 17.7 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| glucagon-like peptide 2 | | | | 2000 | 2021 | 12.5 | low | 0 | 0 | 1 | 3 | 5 | 2 |
| lys-pro-arg-arg-pro-tyr-vip(7-28) | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| humulin s | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| oxyntomodulin | | | | 1994 | 2018 | 24.6 | low | 0 | 0 | 21 | 8 | 1 | 0 |
| peptide yy | | | | 2011 | 2019 | 9.0 | low | 3 | 0 | 0 | 0 | 4 | 0 |
| catalpol | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thromboplastin | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| exendin 3 | | | | 1998 | 2021 | 18.0 | medium | 0 | 0 | 2 | 0 | 0 | 1 |
| guanosine | | guanosines;
purines D-ribonucleoside | fundamental metabolite | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| 3'-o-methylguanosine | | methylguanosine | metabolite | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| leptin | | | | 1997 | 2008 | 21.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Abdominal Pain | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Absence Seizure | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Ischemic Stroke | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Adenoma, alpha-Cell | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adenoma, beta-Cell | 0 | | 1995 | 2017 | 20.2 | low | 0 | 0 | 3 | 0 | 2 | 0 |
| Age-Related Memory Disorders | 0 | | 1999 | 2021 | 14.0 | low | 0 | 0 | 1 | 0 | 0 | 1 |
| Allotriophagy | 0 | | 2016 | 2019 | 7.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Alloxan Diabetes | 0 | | 2003 | 2016 | 14.9 | low | 0 | 0 | 0 | 4 | 3 | 0 |
| Anesthesia | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Anorexia | 0 | | 2004 | 2021 | 9.2 | low | 0 | 0 | 0 | 1 | 4 | 1 |
| Anxiety | 0 | | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Asymptomatic Conditions | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Atherogenesis | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Atherosclerosis | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Autoimmune Diabetes | 0 | | 2011 | 2019 | 9.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Benign Neoplasms | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Binge Eating | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Body Weight | 0 | | 1997 | 2019 | 12.5 | low | 1 | 0 | 2 | 1 | 9 | 0 |
| Bulimia | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Pancreas | 0 | | 1996 | 2017 | 17.0 | low | 0 | 0 | 2 | 0 | 3 | 0 |
| Cancer of the Thyroid | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Carcinoma, Medullary | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cardiac Failure | 0 | | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cardiac Remodeling, Ventricular | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiovascular Stroke | 0 | | 2011 | 2016 | 11.2 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| Cerebral Infarction, Middle Cerebral Artery | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cholera Infantum | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Chronic Pain | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Chronic Pancreatitis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Colicky Pain | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Colitis, Mucous | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Compensatory Hyperinsulinemia | 0 | | 1996 | 2023 | 11.8 | low | 1 | 0 | 1 | 3 | 4 | 2 |
| Complication, Postoperative | 0 | | 2016 | 2021 | 5.5 | low | 2 | 0 | 0 | 0 | 3 | 1 |
| Congenital Hyperinsulinism | 0 | | 2012 | 2023 | 5.6 | low | 2 | 0 | 0 | 0 | 3 | 2 |
| Decerebrate Posturing | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Depression | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetes Mellitus | 0 | | 2003 | 2007 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Diabetes Mellitus, Adult-Onset | 0 | | 1993 | 2019 | 12.4 | low | 6 | 0 | 2 | 4 | 17 | 0 |
| Diabetes Mellitus, Type 1 | 0 | | 2011 | 2019 | 9.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Diabetes Mellitus, Type 2 | 0 | | 1993 | 2019 | 12.4 | low | 6 | 0 | 2 | 4 | 17 | 0 |
| Diabetic Cardiomyopathies | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetic Retinopathy | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diathesis | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Disease Models, Animal | 0 | | 2007 | 2021 | 8.2 | low | 0 | 0 | 0 | 2 | 9 | 3 |
| Dyspepsia | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Emesis | 0 | | 2014 | 2019 | 8.3 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| Familial Hyperinsulinemic Hypoglycemia 1 | 0 | | 2012 | 2023 | 5.6 | low | 2 | 0 | 0 | 0 | 3 | 2 |
| Fasting Hypoglycemia | 0 | | 2008 | 2021 | 8.1 | low | 3 | 0 | 0 | 1 | 10 | 1 |
| Fever | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Glucose Intolerance | 0 | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Heart Failure | 0 | | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Heartburn | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperglycemia | 0 | | 1996 | 2019 | 13.2 | low | 1 | 0 | 1 | 3 | 5 | 0 |
| Hyperglycemia, Postprandial | 0 | | 1996 | 2019 | 13.2 | low | 1 | 0 | 1 | 3 | 5 | 0 |
| Hyperinsulinism | 0 | | 1996 | 2023 | 11.8 | low | 1 | 0 | 1 | 3 | 4 | 2 |
| Hyperlipemia | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperlipidemias | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperphagia | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypoglycemia | 0 | | 2008 | 2021 | 8.1 | low | 3 | 0 | 0 | 1 | 10 | 1 |
| Hypothermia | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypothermia, Accidental | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Impaired Glucose Tolerance | 0 | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Indigestion | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infarction, Middle Cerebral Artery | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Inflammation | 0 | | 2009 | 2016 | 10.4 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| Injuries | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Injury, Ischemia-Reperfusion | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Injury, Myocardial Reperfusion | 0 | | 2011 | 2019 | 10.3 | low | 1 | 0 | 0 | 0 | 7 | 0 |
| Innate Inflammatory Response | 0 | | 2009 | 2016 | 10.4 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| Insulin Resistance | 0 | | 1999 | 2018 | 13.5 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| Insulin Sensitivity | 0 | | 1999 | 2018 | 13.5 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| Insulinoma | 0 | | 1995 | 2017 | 20.2 | low | 0 | 0 | 3 | 0 | 2 | 0 |
| Intestinal Diseases | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Irritable Bowel Syndrome | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ischemic Stroke | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Leanness | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Memory Disorders | 0 | | 1999 | 2021 | 14.0 | low | 0 | 0 | 1 | 0 | 0 | 1 |
| Morbid Obesity | 0 | | 2007 | 2021 | 8.2 | low | 1 | 0 | 0 | 1 | 2 | 1 |
| Mucositis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscle Contraction | 0 | | 2005 | 2007 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Myocardial Infarction | 0 | | 2011 | 2016 | 11.2 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| Nausea | 0 | | 2011 | 2019 | 8.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Neoplasms | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nerve Pain | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Nervous System Diseases | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nervous System Disorders | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neuralgia | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Obesity | 0 | | 2003 | 2020 | 11.2 | low | 4 | 0 | 0 | 5 | 13 | 0 |
| Obesity, Morbid | 0 | | 2007 | 2021 | 8.2 | low | 1 | 0 | 0 | 1 | 2 | 1 |
| Pain, Chronic | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Pancreatic Neoplasms | 0 | | 1996 | 2017 | 17.0 | low | 0 | 0 | 2 | 0 | 3 | 0 |
| Pancreatitis, Chronic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Peripheral Nerve Injuries | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Peripheral Nerve Injury | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Postoperative Complications | 0 | | 2016 | 2021 | 5.5 | low | 2 | 0 | 0 | 0 | 3 | 1 |
| Pyrexia | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pyrosis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Reperfusion Injury | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Seizures | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sensitivity and Specificity | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Thyroid Neoplasms | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Vomiting | 0 | | 2014 | 2019 | 8.3 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| Weight Gain | 0 | | 2014 | 2018 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Weight Loss | 0 | | 2014 | 2021 | 6.3 | low | 1 | 0 | 0 | 0 | 5 | 1 |
| Weight Reduction | 0 | | 2014 | 2021 | 6.3 | low | 1 | 0 | 0 | 0 | 5 | 1 |
| Wounds and Injuries | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Deoxynivalenol (Vomitoxin)-Induced Anorexia Is Induced by the Release of Intestinal Hormones in Mice.Toxins, , 07-22, Volume: 13, Issue:8, 2021
Hypophagia induced by hindbrain serotonin is mediated through central GLP-1 signaling and involves 5-HT2C and 5-HT3 receptor activation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 44, Issue:10, 2019
Endogenous GLP-1 in lateral septum contributes to stress-induced hypophagia.Physiology & behavior, , 08-01, Volume: 192, 2018
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea.Physiology & behavior, , Jan-01, Volume: 153, 2016
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia.Diabetes, obesity & metabolism, , Volume: 13 Suppl 1, 2011
Attenuation of lipopolysaccharide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R.American journal of physiology. Regulatory, integrative and comparative physiology, , Volume: 287, Issue:5, 2004
Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms.Neurogastroenterology and motility, , Volume: 31, Issue:10, 2019
Role of lateral septum glucagon-like peptide 1 receptors in food intake.American journal of physiology. Regulatory, integrative and comparative physiology, , 07-01, Volume: 311, Issue:1, 2016
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.European journal of pharmacology, , Jul-30, Volume: 568, Issue:1-3, 2007
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.Diabetologia, , Volume: 46, Issue:2, 2003
GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist.The Journal of clinical endocrinology and metabolism, , 06-01, Volume: 104, Issue:6, 2019
Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.Diabetes, , Volume: 60, Issue:5, 2011
GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist.The Journal of clinical endocrinology and metabolism, , 06-01, Volume: 104, Issue:6, 2019
Intestinal electrical stimulation attenuates hyperglycemia and prevents loss of pancreatic β cells in type 2 diabetic Goto-Kakizaki rats.Nutrition & diabetes, , 02-06, Volume: 9, Issue:1, 2019
Functional and Molecular Adaptations of Enteroendocrine L-Cells in Male Obese Mice Are Associated With Preservation of Pancreatic α-Cell Function and Prevention of Hyperglycemia.Endocrinology, , Volume: 157, Issue:10, 2016
Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.The Journal of endocrinology, , Volume: 229, Issue:1, 2016
Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.Diabetes, , Volume: 65, Issue:8, 2016
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.International journal of obesity (2005), , Volume: 40, Issue:11, 2016
Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.Diabetologia, , Volume: 58, Issue:12, 2015
Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.Diabetes, obesity & metabolism, , Volume: 17, Issue:9, 2015
GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.Diabetes, , Volume: 63, Issue:12, 2014
Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.Diabetes, , Volume: 62, Issue:9, 2013
GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery.Diabetes care, , Volume: 36, Issue:7, 2013
Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?Diabetes, , Volume: 61, Issue:9, 2012
The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Diabetes, , Volume: 61, Issue:9, 2012
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser.Diabetologia, , Volume: 54, Issue:2, 2011
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.Diabetologia, , Volume: 54, Issue:2, 2011
Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.Endocrinology, , Volume: 149, Issue:10, 2008
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.The Journal of endocrinology, , Volume: 192, Issue:2, 2007
GLP-1 signalling and effects on glucose metabolism in myocytes from type 2 diabetic patients.International journal of molecular medicine, , Volume: 16, Issue:4, 2005
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.The Journal of endocrinology, , Volume: 185, Issue:2, 2005
Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39).Metabolism: clinical and experimental, , Volume: 48, Issue:6, 1999
Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.Diabetes, , Volume: 42, Issue:11, 1993
Obestatin prevents HBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 97, 2018
Intestinal electrical stimulation attenuates hyperglycemia and prevents loss of pancreatic β cells in type 2 diabetic Goto-Kakizaki rats.Nutrition & diabetes, , 02-06, Volume: 9, Issue:1, 2019
Functional and Molecular Adaptations of Enteroendocrine L-Cells in Male Obese Mice Are Associated With Preservation of Pancreatic α-Cell Function and Prevention of Hyperglycemia.Endocrinology, , Volume: 157, Issue:10, 2016
β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.Journal of cellular and molecular medicine, , Volume: 20, Issue:2, 2016
Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.Diabetes, , Volume: 63, Issue:1, 2014
Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a.American journal of physiology. Cell physiology, , Volume: 304, Issue:6, 2013
Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia.The Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:1, 2010
Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:12, 2008
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.The Journal of clinical investigation, , Volume: 115, Issue:12, 2005
Central glucagon-like peptide-I in the control of feeding.Biochemical Society transactions, , Volume: 24, Issue:2, 1996
Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.Diabetes, , 09-01, Volume: 72, Issue:9, 2023
Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge.Diabetes care, , 06-02, Volume: 45, Issue:6, 2022
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats.Neuroscience, , 03-06, Volume: 344, 2017
Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering.Diabetes, , Volume: 63, Issue:10, 2014
Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.Endocrinology, , Volume: 149, Issue:10, 2008
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.The Journal of clinical investigation, , Volume: 115, Issue:12, 2005
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.Diabetologia, , Volume: 46, Issue:2, 2003
Central glucagon-like peptide-I in the control of feeding.Biochemical Society transactions, , Volume: 24, Issue:2, 1996
PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia.The Journal of clinical endocrinology and metabolism, , 07-13, Volume: 106, Issue:8, 2021
Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.Obesity surgery, , Volume: 29, Issue:7, 2019
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.Diabetologia, , Volume: 60, Issue:3, 2017
Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats.Neuroscience, , 03-06, Volume: 344, 2017
Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties.Journal of inherited metabolic disease, , Volume: 40, Issue:4, 2017
Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Postprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology.Hormone research in paediatrics, , Volume: 85, Issue:2, 2016
Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.Gastroenterology, , Volume: 146, Issue:3, 2014
Hypoglycemia after gastric bypass: the dark side of GLP-1.Gastroenterology, , Volume: 146, Issue:3, 2014
Correction of postprandial hypoglycemia after gastric bypass.Gastroenterology, , Volume: 146, Issue:3, 2014
Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.The Journal of biological chemistry, , Sep-19, Volume: 283, Issue:38, 2008
β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.Journal of cellular and molecular medicine, , Volume: 20, Issue:2, 2016
Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets.International journal of molecular medicine, , Volume: 36, Issue:1, 2015
GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering.Diabetes, , Volume: 63, Issue:10, 2014
Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion.Molecular biology reports, , Volume: 41, Issue:6, 2014
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation.Peptides, , Volume: 30, Issue:9, 2009
The Effects of Sleeve Gastrectomy on Glucose Metabolism and Glucagon-Like Peptide 1 in Goto-Kakizaki Rats.Journal of diabetes research, , Volume: 2018, 2018
Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.Diabetologia, , Volume: 59, Issue:12, 2016
Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice.American journal of physiology. Endocrinology and metabolism, , 05-15, Volume: 310, Issue:10, 2016
Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.Diabetes, , Volume: 62, Issue:9, 2013
Reappraisal of the intravenous glucose tolerance index for a simple assessment of insulin sensitivity in mice.American journal of physiology. Regulatory, integrative and comparative physiology, , Volume: 296, Issue:5, 2009
Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.Endocrinology, , Volume: 149, Issue:10, 2008
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.The Journal of clinical investigation, , Volume: 115, Issue:12, 2005
Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice.The American journal of physiology, , Volume: 277, Issue:6, 1999
Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis.Current radiopharmaceuticals, , Volume: 10, Issue:1, 2017
Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.European journal of nuclear medicine and molecular imaging, , Volume: 38, Issue:6, 2011
Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.American journal of physiology. Endocrinology and metabolism, , Volume: 279, Issue:1, 2000
Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.Endocrinology, , Volume: 137, Issue:10, 1996
Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas.The Biochemical journal, , Aug-15, Volume: 310 ( Pt 1), 1995
Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning.Cardiovascular research, , Volume: 112, Issue:3, 2016
Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression.Cardiology journal, , Volume: 20, Issue:6, 2013
DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 384, Issue:2, 2011
Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.British journal of pharmacology, , Volume: 164, Issue:1, 2011
Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms.Neurogastroenterology and motility, , Volume: 31, Issue:10, 2019
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea.Physiology & behavior, , Jan-01, Volume: 153, 2016
Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.Scandinavian journal of gastroenterology, , Volume: 46, Issue:4, 2011
A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.Metabolic syndrome and related disorders, , Volume: 18, Issue:9, 2020
Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery.Cell reports, , 02-05, Volume: 26, Issue:6, 2019
Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice.American journal of physiology. Endocrinology and metabolism, , 05-15, Volume: 310, Issue:10, 2016
Functional and Molecular Adaptations of Enteroendocrine L-Cells in Male Obese Mice Are Associated With Preservation of Pancreatic α-Cell Function and Prevention of Hyperglycemia.Endocrinology, , Volume: 157, Issue:10, 2016
Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.The Journal of endocrinology, , Volume: 229, Issue:1, 2016
Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.American journal of physiology. Endocrinology and metabolism, , Apr-01, Volume: 310, Issue:7, 2016
Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.Diabetes, obesity & metabolism, , Volume: 17, Issue:9, 2015
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.Diabetologia, , Volume: 58, Issue:12, 2015
GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.Diabetes, , Volume: 63, Issue:12, 2014
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.American journal of physiology. Regulatory, integrative and comparative physiology, , Mar-01, Volume: 306, Issue:5, 2014
Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2.The Journal of endocrinology, , Volume: 213, Issue:3, 2012
Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Mar-09, Volume: 31, Issue:10, 2011
GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide.Obesity (Silver Spring, Md.), , Volume: 16, Issue:7, 2008
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.The Journal of endocrinology, , Volume: 192, Issue:2, 2007
Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.Biological chemistry, , Volume: 388, Issue:2, 2007
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.The Journal of endocrinology, , Volume: 185, Issue:2, 2005
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.Diabetologia, , Volume: 46, Issue:2, 2003
Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?Nutrients, , Feb-26, Volume: 13, Issue:3, 2021
Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.Obesity surgery, , Volume: 29, Issue:7, 2019
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.International journal of obesity (2005), , Volume: 40, Issue:11, 2016
The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients.International journal of molecular medicine, , Volume: 19, Issue:6, 2007
Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis.Current radiopharmaceuticals, , Volume: 10, Issue:1, 2017
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia.Diabetes, obesity & metabolism, , Volume: 13 Suppl 1, 2011
Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.European journal of nuclear medicine and molecular imaging, , Volume: 38, Issue:6, 2011
Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.American journal of physiology. Endocrinology and metabolism, , Volume: 279, Issue:1, 2000
Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.Endocrinology, , Volume: 137, Issue:10, 1996
PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia.The Journal of clinical endocrinology and metabolism, , 07-13, Volume: 106, Issue:8, 2021
Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.Obesity surgery, , Volume: 29, Issue:7, 2019
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Postprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology.Hormone research in paediatrics, , Volume: 85, Issue:2, 2016
Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms.Neurogastroenterology and motility, , Volume: 31, Issue:10, 2019
The differential antiemetic properties of GLP-1 receptor antagonist, exendin (9-39) in Suncus murinus (house musk shrew).Neuropharmacology, , Volume: 83, 2014
Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men.The American journal of clinical nutrition, , Volume: 100, Issue:2, 2014
Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?Nutrients, , Feb-26, Volume: 13, Issue:3, 2021
A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.Metabolic syndrome and related disorders, , Volume: 18, Issue:9, 2020
Hypophagia induced by hindbrain serotonin is mediated through central GLP-1 signaling and involves 5-HT2C and 5-HT3 receptor activation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 44, Issue:10, 2019
Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.International journal of obesity (2005), , Volume: 40, Issue:11, 2016
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.American journal of physiology. Regulatory, integrative and comparative physiology, , Mar-01, Volume: 306, Issue:5, 2014
Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.Diabetes, , 09-01, Volume: 72, Issue:9, 2023
Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge.Diabetes care, , 06-02, Volume: 45, Issue:6, 2022
Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.British journal of clinical pharmacology, , Volume: 84, Issue:3, 2018
Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties.Journal of inherited metabolic disease, , Volume: 40, Issue:4, 2017
GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.Diabetes, , Volume: 61, Issue:10, 2012
Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.Diabetes, , 09-01, Volume: 72, Issue:9, 2023
Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge.Diabetes care, , 06-02, Volume: 45, Issue:6, 2022
Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.British journal of clinical pharmacology, , Volume: 84, Issue:3, 2018
Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties.Journal of inherited metabolic disease, , Volume: 40, Issue:4, 2017
GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.Diabetes, , Volume: 61, Issue:10, 2012
Intestinal electrical stimulation attenuates hyperglycemia and prevents loss of pancreatic β cells in type 2 diabetic Goto-Kakizaki rats.Nutrition & diabetes, , 02-06, Volume: 9, Issue:1, 2019
The Effects of Sleeve Gastrectomy on Glucose Metabolism and Glucagon-Like Peptide 1 in Goto-Kakizaki Rats.Journal of diabetes research, , Volume: 2018, 2018
Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice.American journal of physiology. Endocrinology and metabolism, , 05-15, Volume: 310, Issue:10, 2016
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea.Physiology & behavior, , Jan-01, Volume: 153, 2016
Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet.Behavioural pharmacology, , Volume: 25, Issue:1, 2014
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.American journal of physiology. Regulatory, integrative and comparative physiology, , Mar-01, Volume: 306, Issue:5, 2014
Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.Medical science monitor basic research, , Jan-01, Volume: 19, 2013
Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass.Physiology & behavior, , Sep-10, Volume: 121, 2013
Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.Endocrinology, , Volume: 152, Issue:8, 2011
Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, , Volume: 59, Issue:3, 2008
Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.Endocrinology, , Volume: 140, Issue:1, 1999
Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents.FEBS letters, , Sep-29, Volume: 415, Issue:2, 1997
Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.Diabetologia, , Volume: 59, Issue:12, 2016
Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.Diabetes, , Volume: 63, Issue:1, 2014
Synthesis and evaluation of [18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass.Nuclear medicine and biology, , Volume: 39, Issue:2, 2012
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.The Journal of endocrinology, , Volume: 192, Issue:2, 2007
Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.Biological chemistry, , Volume: 388, Issue:2, 2007
Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats.Journal of molecular endocrinology, , Volume: 35, Issue:1, 2005
Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.International journal of molecular medicine, , Volume: 11, Issue:6, 2003
GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist.The Journal of clinical endocrinology and metabolism, , 06-01, Volume: 104, Issue:6, 2019
Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.Diabetes, , Volume: 60, Issue:5, 2011
GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist.The Journal of clinical endocrinology and metabolism, , 06-01, Volume: 104, Issue:6, 2019
Intestinal electrical stimulation attenuates hyperglycemia and prevents loss of pancreatic β cells in type 2 diabetic Goto-Kakizaki rats.Nutrition & diabetes, , 02-06, Volume: 9, Issue:1, 2019
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.International journal of obesity (2005), , Volume: 40, Issue:11, 2016
Functional and Molecular Adaptations of Enteroendocrine L-Cells in Male Obese Mice Are Associated With Preservation of Pancreatic α-Cell Function and Prevention of Hyperglycemia.Endocrinology, , Volume: 157, Issue:10, 2016
Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.The Journal of endocrinology, , Volume: 229, Issue:1, 2016
Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.Diabetes, , Volume: 65, Issue:8, 2016
Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.Diabetes, obesity & metabolism, , Volume: 17, Issue:9, 2015
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.Diabetologia, , Volume: 58, Issue:12, 2015
GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.Diabetes, , Volume: 63, Issue:12, 2014
GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery.Diabetes care, , Volume: 36, Issue:7, 2013
Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.Diabetes, , Volume: 62, Issue:9, 2013
Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?Diabetes, , Volume: 61, Issue:9, 2012
The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Diabetes, , Volume: 61, Issue:9, 2012
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser.Diabetologia, , Volume: 54, Issue:2, 2011
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.Diabetologia, , Volume: 54, Issue:2, 2011
Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.Endocrinology, , Volume: 149, Issue:10, 2008
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.The Journal of endocrinology, , Volume: 192, Issue:2, 2007
GLP-1 signalling and effects on glucose metabolism in myocytes from type 2 diabetic patients.International journal of molecular medicine, , Volume: 16, Issue:4, 2005
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.The Journal of endocrinology, , Volume: 185, Issue:2, 2005
Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39).Metabolism: clinical and experimental, , Volume: 48, Issue:6, 1999
Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.Diabetes, , Volume: 42, Issue:11, 1993
Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke.Basic research in cardiology, , 05-03, Volume: 116, Issue:1, 2021
GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF-κB pathway in neuropathic pain mice.Neurobiology of learning and memory, , Volume: 182, 2021
The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice.Peptides, , Volume: 135, 2021
The intestine responds to heart failure by enhanced mitochondrial fusion through glucagon-like peptide-1 signalling.Cardiovascular research, , Nov-01, Volume: 115, Issue:13, 2019
Endogenous GLP-1 in lateral septum contributes to stress-induced hypophagia.Physiology & behavior, , 08-01, Volume: 192, 2018
Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.Drug research, , Volume: 67, Issue:12, 2017
Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning.Cardiovascular research, , Volume: 112, Issue:3, 2016
Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.Circulation. Heart failure, , Volume: 9, Issue:1, 2016
The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice.European journal of pharmacology, , Oct-05, Volume: 764, 2015
Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression.Cardiology journal, , Volume: 20, Issue:6, 2013
DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 384, Issue:2, 2011
Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.American journal of physiology. Endocrinology and metabolism, , Volume: 299, Issue:4, 2010
Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.Biological chemistry, , Volume: 388, Issue:2, 2007
Intestinal electrical stimulation attenuates hyperglycemia and prevents loss of pancreatic β cells in type 2 diabetic Goto-Kakizaki rats.Nutrition & diabetes, , 02-06, Volume: 9, Issue:1, 2019
Functional and Molecular Adaptations of Enteroendocrine L-Cells in Male Obese Mice Are Associated With Preservation of Pancreatic α-Cell Function and Prevention of Hyperglycemia.Endocrinology, , Volume: 157, Issue:10, 2016
β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.Journal of cellular and molecular medicine, , Volume: 20, Issue:2, 2016
Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.Diabetes, , Volume: 63, Issue:1, 2014
Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a.American journal of physiology. Cell physiology, , Volume: 304, Issue:6, 2013
Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia.The Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:1, 2010
Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:12, 2008
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.The Journal of clinical investigation, , Volume: 115, Issue:12, 2005
Central glucagon-like peptide-I in the control of feeding.Biochemical Society transactions, , Volume: 24, Issue:2, 1996
Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.Diabetes, , 09-01, Volume: 72, Issue:9, 2023
Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge.Diabetes care, , 06-02, Volume: 45, Issue:6, 2022
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats.Neuroscience, , 03-06, Volume: 344, 2017
Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering.Diabetes, , Volume: 63, Issue:10, 2014
Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.Endocrinology, , Volume: 149, Issue:10, 2008
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.The Journal of clinical investigation, , Volume: 115, Issue:12, 2005
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.Diabetologia, , Volume: 46, Issue:2, 2003
Central glucagon-like peptide-I in the control of feeding.Biochemical Society transactions, , Volume: 24, Issue:2, 1996
PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia.The Journal of clinical endocrinology and metabolism, , 07-13, Volume: 106, Issue:8, 2021
Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.Obesity surgery, , Volume: 29, Issue:7, 2019
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats.Neuroscience, , 03-06, Volume: 344, 2017
Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.Diabetologia, , Volume: 60, Issue:3, 2017
Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties.Journal of inherited metabolic disease, , Volume: 40, Issue:4, 2017
Postprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology.Hormone research in paediatrics, , Volume: 85, Issue:2, 2016
Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Correction of postprandial hypoglycemia after gastric bypass.Gastroenterology, , Volume: 146, Issue:3, 2014
Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.Gastroenterology, , Volume: 146, Issue:3, 2014
Hypoglycemia after gastric bypass: the dark side of GLP-1.Gastroenterology, , Volume: 146, Issue:3, 2014
Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.The Journal of biological chemistry, , Sep-19, Volume: 283, Issue:38, 2008
β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.Journal of cellular and molecular medicine, , Volume: 20, Issue:2, 2016
Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets.International journal of molecular medicine, , Volume: 36, Issue:1, 2015
GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering.Diabetes, , Volume: 63, Issue:10, 2014
Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion.Molecular biology reports, , Volume: 41, Issue:6, 2014
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation.Peptides, , Volume: 30, Issue:9, 2009
The Effects of Sleeve Gastrectomy on Glucose Metabolism and Glucagon-Like Peptide 1 in Goto-Kakizaki Rats.Journal of diabetes research, , Volume: 2018, 2018
Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice.American journal of physiology. Endocrinology and metabolism, , 05-15, Volume: 310, Issue:10, 2016
Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.Diabetologia, , Volume: 59, Issue:12, 2016
Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.Diabetes, , Volume: 62, Issue:9, 2013
Reappraisal of the intravenous glucose tolerance index for a simple assessment of insulin sensitivity in mice.American journal of physiology. Regulatory, integrative and comparative physiology, , Volume: 296, Issue:5, 2009
Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.Endocrinology, , Volume: 149, Issue:10, 2008
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.The Journal of clinical investigation, , Volume: 115, Issue:12, 2005
Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice.The American journal of physiology, , Volume: 277, Issue:6, 1999
Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis.Current radiopharmaceuticals, , Volume: 10, Issue:1, 2017
Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.European journal of nuclear medicine and molecular imaging, , Volume: 38, Issue:6, 2011
Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.American journal of physiology. Endocrinology and metabolism, , Volume: 279, Issue:1, 2000
Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.Endocrinology, , Volume: 137, Issue:10, 1996
Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas.The Biochemical journal, , Aug-15, Volume: 310 ( Pt 1), 1995
Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning.Cardiovascular research, , Volume: 112, Issue:3, 2016
Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression.Cardiology journal, , Volume: 20, Issue:6, 2013
Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.British journal of pharmacology, , Volume: 164, Issue:1, 2011
DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 384, Issue:2, 2011
Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?Nutrients, , Feb-26, Volume: 13, Issue:3, 2021
Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.Obesity surgery, , Volume: 29, Issue:7, 2019
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.International journal of obesity (2005), , Volume: 40, Issue:11, 2016
The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients.International journal of molecular medicine, , Volume: 19, Issue:6, 2007
Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis.Current radiopharmaceuticals, , Volume: 10, Issue:1, 2017
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia.Diabetes, obesity & metabolism, , Volume: 13 Suppl 1, 2011
Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.European journal of nuclear medicine and molecular imaging, , Volume: 38, Issue:6, 2011
Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.American journal of physiology. Endocrinology and metabolism, , Volume: 279, Issue:1, 2000
Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.Endocrinology, , Volume: 137, Issue:10, 1996
Hypophagia induced by hindbrain serotonin is mediated through central GLP-1 signaling and involves 5-HT2C and 5-HT3 receptor activation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 44, Issue:10, 2019
Role of lateral septum glucagon-like peptide 1 receptors in food intake.American journal of physiology. Regulatory, integrative and comparative physiology, , 07-01, Volume: 311, Issue:1, 2016
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea.Physiology & behavior, , Jan-01, Volume: 153, 2016
PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia.The Journal of clinical endocrinology and metabolism, , 07-13, Volume: 106, Issue:8, 2021
Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.Obesity surgery, , Volume: 29, Issue:7, 2019
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Postprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology.Hormone research in paediatrics, , Volume: 85, Issue:2, 2016
Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms.Neurogastroenterology and motility, , Volume: 31, Issue:10, 2019
Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men.The American journal of clinical nutrition, , Volume: 100, Issue:2, 2014
The differential antiemetic properties of GLP-1 receptor antagonist, exendin (9-39) in Suncus murinus (house musk shrew).Neuropharmacology, , Volume: 83, 2014
Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans.International journal of cardiology, , Jan-01, Volume: 274, 2019
Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning.Cardiovascular research, , Volume: 112, Issue:3, 2016
Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion.Molecular biology reports, , Volume: 41, Issue:6, 2014
Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression.Cardiology journal, , Volume: 20, Issue:6, 2013
Postconditioning with curaglutide, a novel GLP-1 analog, protects against heart ischemia-reperfusion injury in an isolated rat heart.Regulatory peptides, , Oct-10, Volume: 178, Issue:1-3, 2012
DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 384, Issue:2, 2011
Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.British journal of pharmacology, , Volume: 164, Issue:1, 2011
Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?Nutrients, , Feb-26, Volume: 13, Issue:3, 2021
A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.Metabolic syndrome and related disorders, , Volume: 18, Issue:9, 2020
Hypophagia induced by hindbrain serotonin is mediated through central GLP-1 signaling and involves 5-HT2C and 5-HT3 receptor activation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 44, Issue:10, 2019
Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, , Volume: 12, Issue:6, 2016
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.International journal of obesity (2005), , Volume: 40, Issue:11, 2016
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.American journal of physiology. Regulatory, integrative and comparative physiology, , Mar-01, Volume: 306, Issue:5, 2014
Safety/Toxicity (3)
Long-term Use (2)
Pharmacokinetics (3)
| Article | Year |
|---|
Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.
British journal of clinical pharmacology, , Volume: 84, Issue:3 | 2018 |
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.
Diabetes, obesity & metabolism, , Volume: 20, Issue:2 | 2018 |
Hindbrain glucagon-like peptide-1 neurons track intake volume and contribute to injection stress-induced hypophagia in meal-entrained rats.
American journal of physiology. Regulatory, integrative and comparative physiology, , 05-15, Volume: 310, Issue:10 | 2016 |
Dosage (6)
| Article | Year |
|---|
Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge.
Diabetes care, , 06-02, Volume: 45, Issue:6 | 2022 |
Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.
British journal of clinical pharmacology, , Volume: 84, Issue:3 | 2018 |
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.
Diabetes, obesity & metabolism, , Volume: 20, Issue:2 | 2018 |
Indirect effects of glucagon-like peptide-1 receptor agonist exendin-4 on the peripheral circadian clocks in mice.
PloS one, , Volume: 8, Issue:11 | 2013 |
Postconditioning with curaglutide, a novel GLP-1 analog, protects against heart ischemia-reperfusion injury in an isolated rat heart.
Regulatory peptides, , Oct-10, Volume: 178, Issue:1-3 | 2012 |
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.
Regulatory peptides, , Feb-15, Volume: 125, Issue:1-3 | 2005 |